Medical diagnostics company Omega Diagnostics saw a 23% rise in its share price in early trading today.
The rise followed a report in The Financial Times about the company upgrading its plant in Alva, Clackmannanshire for its Covid-19 testing work.
In a statement Omega said that it was “continuing to modify its Alva-based facilitiy to upscale significantly its lateral flow testing production capacity.”
It added: “When contracts or supply agreements are signed to utilise this capacity the company will announce in line with AIM discolosure obigations.”
In November Omega had reported a loss of £1.29m on revenues down 29% to £3.16m in its half yearly results.
Omega said the figures to 30 September were impacted by the effects of Covid-19 on its trading and said the board expects a significantly improved second half performance.
It said at the time that it had an “exciting opportunity” for the roll-out of its AbC-19 rapid test for Covid-19 to the UK Government and other customers.
It also reported at the time that production of the tests was well underway with shipments to Abdingon underway in order for fellow UK Rapid Test Consortium member Abingdon Health to supply AbC-1 Rapid tests to the Department of Health and Social Care.
